DSM & Evonik Collaborate on Marine Algae for Animal Nutrition & Aquaculture

f3d88092-1081-42ee-b8db-9f2c864da629articleimage.jpg

08 Mar 2017 --- Royal DSM and Evonik have announced plans to establish a joint venture producing omega-3 fatty acid products from natural marine algae for the animal nutrition and aquaculture markets. The innovation will enable the sustainable production of omega-3 fatty acids for animal nutrition without using fish oil from wild caught fish.

“Our products will initially target the salmon aquaculture and pet food markets,”

Herman Betten, Global Director External Affairs, Royal DSM, explained to NutritionInsight.

“With currently 17% of the world’s wild caught fish being used to produce fish oil for aquaculture, we believe this is unsustainable.”

“By producing omega 3 with EPA and DHA from algae, we will enable the aquaculture industry to grow sustainably,” notes Betten.

The companies have said that their highly concentrated algal oil is a high value and pure source that will enable the animal nutrition industry to keep up with the increasing demand for these two essential omega-3 fatty acids without endangering fish stocks.

They add that this will contribute to healthy animal nutrition as well as to the ecological balance and biodiversity of the oceans - something they regard as a breakthrough in the industry.

Betten added: “DSM and Evonik are building a facility in response to the anticipated growth from the aquaculture industry for omega-3 with EPA and DHA, with fish oil being a finite resource.”

The alternative omega-3 source is the first to offer both EPA and DHA and will be aimed at initial applications in salmon aquaculture and pet food.

Complimentary Offerings

The companies state that the successful product and process development was only possible thanks to the complementary competencies that Evonik and DSM bring to the collaboration.

DSM has expertise in the cultivation of marine organisms including algae and long-established biotechnology capabilities in development and operations, whilst Evonik's focus has been on developing industrial biotechnology processes and operating competitively large-scale manufacturing sites for fermentative amino acids.

Joint Development

DSM Nutritional Products and Evonik Nutrition & Care will each hold a 50% share in the joint venture and co-own the production facility, which will be built at an existing site of Evonik and is expected to come on stream in 2019. The joint venture plans to invest around US$ 200 million in the facility (USD 100 million by each party over circa 2 years).

The company has set its goals high, with Betten explaining that, “We are initially covering 15% of the current annual demand for EPA and DHA from the salmon aquaculture industry.”

The set-up of the joint venture, to be named Veramaris and headquartered in The Netherlands, will be finalized subject to regulatory approvals and other customary closing conditions.

The joint venture follows the joint development agreement, signed in July 2015. Under this agreement, Evonik and DSM have jointly worked on the development of products and the manufacturing process and explored opportunities for commercialization.

Both companies achieved positive results in the development of the product while extensively working with the entire value chain, including fish feed producers, fish farmers and retailers.

Under the joint development agreement, DSM and Evonik have successfully produced pilot-scale quantities of the algal oil at DSM’s production facility in Kingstree, South Carolina (United States).

Customers will be able to receive sizeable quantities of the product for market development while the construction of the new manufacturing plant is underway.

Sustainability in the Aquaculture industry

The algal oil from DSM and Evonik means that the vision of salmon farming without using fish-based resources is – for the first time – becoming realistic. By replacing fish oil in salmon feed with this EPA and DHA rich alternative, the fish-in-fish-out ratio could be reduced significantly.

The two companies state that this alternative will enable the aquaculture industry to continue to grow sustainably.

Worldwide fish oil production is approximately one million metric tons per year. Most of the fish oil is used in aquaculture, mainly for fat-rich fish species, such as salmon. The limited wild fish stocks restrict the amount of fish oil available and thus the growth of the aquaculture industry.

Currently, the industry uses about 75% of the annual production of fish oil.

Growth in the Pet Food Market

Just like humans, animals also need their daily intake of essential, long-chain polyunsaturated fatty acids in their diet to ensure healthy growth.

Until now, these fatty acids have been added to aquaculture feed and pet food almost exclusively from marine sources such as fish oil and fishmeal.

As the new algal oil can be applied in feed production in the same way as fish oil, it can easily be introduced by feed and pet food producers, offering a sustainable non-fish alternative.

The omega 3 pet food market is growing too. According to Innova Market Insights, launches of pet foods featuring omega 3 rose 2.5% from 2015 to 2015, indicating that there is potential for the companies to really dominate this area.

DSM and Evonik are also pursuing applications of their algal oil for other aquatic and terrestrial animal species.

by Hannah Gardiner

To get in touch with this editor, email hannah@cnsmedia.com

Related Articles

Nutrition & Health News

“Dodgy food claims”: European consumer group campaigns as “nutrient profiles” delays hit 9-year mark

23 Jan 2018 --- The European Consumer Organization, BEUC and its member organizations from 11 countries (see below) are denouncing what it calls “the EU Commission’s long-standing failure to clear the market of bogus food claims.” It is common to see foods and drinks loaded with sugar, salt or fat with nutrition claims such as “high in fibers,” “B vitamins” or health claims like “boosts your immune system.” Those messages give: “a healthy halo to unhealthy products and mislead consumers as to the actual nutritional content of the food they buy.”

Nutrition & Health News

Teens' alcohol consumption can predict risk of liver problems in adulthood

22 Jan 2018 --- Adolescent drinking can predict the risk of developing liver disease later in life, confirms a major new study conducted in Sweden. Alcohol is the leading cause of liver cirrhosis and liver-related deaths, and guidelines for safe alcohol intake in men might have to be revised downwards, the researchers report in the Journal of Hepatology. Current recommended cut-off levels in some countries suggest that safe alcohol consumption for men to avoid alcoholic liver disease is 30 grams per day, roughly equivalent to three drinks.

Business News

Antibiotic innovation: Research group calls for 50 percent investment increase as resistance threats intensify

22 Jan 2018 --- The World Health Organization (WHO) has deemed antibiotic resistance to be one of the three greatest threats to human health today, as bacteria become increasingly resistant and too few treatments are being developed to combat them. The research project DRIVE-AB, a consortium managed by the University of Geneva (UNIGE) and AstraZeneca, has determined that a market entry reward of $1 billion per antibiotic globally could significantly increase the number of new antibiotics coming to the market in the next 30 years.

Business News

Frutarom takes full ownership of Enzymotec, sells krill oil business to Aker BioMarine

19 Jan 2018 --- Frutarom Industries has completed its acquisition of full ownership of Enzymotec. Upon completion of the transaction on January 11, 2018, Enzymotec shares were delisted from trading on NASDAQ and it ceased to be a public company. Frutarom reports that it is working towards implementing the full merger plan of all Enzymotec activities through the rapid, efficient and comprehensive integration of both companies’ activities in the areas of management, R&D, sales and marketing, production and supply chain. As part of its merger plan, Frutarom has announced the sale of Enzymotec’s krill oil business to Aker BioMarine.

Regulatory News

EFSA rejects Unilever black tea health claim

18 Jan 2018 --- The European Food and Safety Authority (EFSA) has rejected a health claim regarding black tea’s effects on the maintenance of normal endothelium-dependent vasodilation in adults. The application, submitted for authorization of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 by Unilever, pertained to “black tea beverages, either freshly prepared or reconstituted from water extract powders of black tea, characterized by the content of flavanols (expressed as catechins plus theaflavins) of at least 30 mg per 200 ml serving.” 

More Articles
URL : http://www.nutritioninsight.com:80/news/dsm-evonik-collaborate-on-marine-algae-for-animal-nutrition-aquaculture.html